07:00 , Oct 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Penicillin binding protein 2a (PBP2a)

Infectious disease INDICATION: Staphylococcus In vitro and mouse studies suggest combining three β-lactam antibiotics that allosterically bind PBP2a could help treat methicillin-resistant Staphylococcus aureus (MRSA) infection. In cultures of the MRSA N315 strain, a combination...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Ceftaroline fosamil: Development discontinued

Dainippon Sumitomo disclosed in its earnings for the fiscal year ended March 31 that it discontinued development of DSP-5990, which was in Phase I testing to treat MRSA infection. The company said the antibiotic did...
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Crystal structures of Staphylococcus aureus penicillin binding protein 2a (PBP2a) In vitro studies identified an allosteric site on PBP2a that could...
07:00 , Apr 5, 2012 |  BC Innovations  |  Cover Story

MRSA sensitivity training

Researchers at Merck & Co. Inc. have identified targets in methicillin-resistant Staphylococcus aureus that synergize with b-lactam antibiotic targets to restore antibiotic sensitivity. 1 The findings suggest it may now be possible to use combinations...
07:00 , Sep 13, 2010 |  BioCentury  |  Regulation

Complicated but uncontroversial

Last week's FDA panel meeting to discuss ceftaroline from Forest Laboratories Inc. was devoid of the controversy that has surrounded reviews of other antibiotics to treat either community-acquired bacterial pneumonia or complicated skin and skin...
07:00 , May 31, 2010 |  BC Week In Review  |  Company News

AdvanDx, Inverness sales and marketing update

AdvanDx launched the BinaxNOW PBP2a test in the U.S. to identify methicillin-resistant Staphylococcus aureus (MRSA). The test detects the penicillin-binding protein (PBP) 2a in blood samples that have tested positive for S. aureus. AdvanDx has...
07:00 , Jul 29, 2002 |  BC Week In Review  |  Clinical News

Cephalosporin prodrug: ETRX said partner JNJ's Pharmaceutical R&D subsidiary started a Phase I trial of its cephalosporin prodrug

Essential Therapeutics Inc. (ETRX), Waltham, Mass.   Johnson & Johnson (JNJ), New Brunswick, N.J.   Product: Cephalosporin prodrug   Business: Infectious diseases   Therapeutic category: Bacterial infection   Target: Penicillin binding protein (PBP) 2a  ...
08:00 , Feb 1, 1999 |  BC Week In Review  |  Company News

Merck Research Laboratories other research news

Merck published in Science the synthesis of L-786,392, which was designed to have higher affinity than currently used antibiotics such as methicillin and vancomycin for the penicillin-binding proteins (PBPs) that contribute to bacterial resistance to...